Liminatus Pharma (formerly known as Iris Acquisition) is a pre‑clinical‑stage immuno‑oncology company. It develops a second-generation CD47-blockade antibody designed to prevent the induction of anemia and thrombocytopenia observed with first-generation CD47 blockades.